64401-55-4

Usage

Uses

Used in Pharmaceutical Production:
Ethyl-5-amino-2-chlorobenzoate is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new medicines. Its unique chemical structure allows it to be a key component in the formulation of drugs targeting specific medical conditions.
Used in Organic Synthesis:
In the field of organic chemistry, Ethyl-5-amino-2-chlorobenzoate serves as a versatile intermediate, enabling the synthesis of a range of organic compounds. Its reactivity and functional groups make it suitable for use in various chemical reactions, facilitating the creation of new organic molecules with diverse applications.
Used in Research and Development:
Ethyl-5-amino-2-chlorobenzoate is also employed in research settings to explore its potential biological activity and investigate its role in the development of innovative therapeutic agents. Scientists use Ethyl-5-amino-2-chlorobenzoate to study its interactions with biological systems and understand its potential effects on human health and disease treatment.

InChI:InChI=1/C9H10ClNO2/c1-2-13-9(12)7-5-6(11)3-4-8(7)10/h3-5H,2,11H2,1H3

Upstream product

• 16588-17-3 ethyl ester of 2-chloro-5-nitrobenzoic acid 
• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 64-17-5 ethanol 
• 89-54-3 2-chloro-5-aminobenzoic acid 

Downstream Products

• 1261078-75-4 5-(6-nitroquinoxalin-3-ylamino)-2-chlorobenzoic acid 
• 1333465-93-2 ethyl 5-(6-nitroquinoxalin-3-ylamino)-2-chlorobenzoate 
• 1569986-10-2 2-chloro-5-(6-chloro-pyrimidin-4-ylamino)-benzoic acid ethyl ester 
• 1569982-08-6 ethyl 2-chloro-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzoate 
• 1569981-80-1 2-chloro-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzohydrazide 
• 1569981-75-4 N-(3-((1H-benzo[d]imidazol-1-yl)methyl)-4-chlorophenyl)-6-(2-methoxyphenyl)pyrimidin-4-amine 
• 1569982-16-6 {2-chloro-5-[6-(2-methoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-methanol 
• 1569982-13-3 (2-chloro-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)phenyl)(pyrrolidin-1-yl)methanone 
• 1569982-31-5 2-(2-chloro-5-(6-(2-methoxyphenyl)pyrimidin-4-ylamino)benzyl)isoindoline-1,3-dione 
• 1569986-13-5 (4-chloro-3-chloromethyl-phenyl)-[6-(2-methoxy-phenyl)-pyrimidin-4-yl]-amine 
• 752231-43-9 ethyl 2-chloro-5-(5-formylfuran-2-yl)benzoate 
• 355142-36-8 2-chloro-5-(5-formylfuran-2-yl)benzoic acid 

Relevant academic research and scientific papers

FURANE DERIVATIVES AS INHIBITORS OF ATAD2

The invention relates to fur an e derivatives of formula (I) as inhibitors of ATAD2, a process for their preparation and use thereof.

NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS

Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents.

BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Design and synthesis of small molecule RhoA inhibitors: A new promising therapy for cardiovascular diseases?

RhoA is a member of Rho GTPases, a subgroup of the Ras superfamily of small GTP-binding proteins. RhoA, as an important regulator of diverse cellular signaling pathways, plays significant roles in cytoskeletal organization, transcription, and cell-cycle progression. The RhoA/ROCK inhibitors have emerged as a new promising treatment for cardiovascular diseases. However, to date, RhoA inhibitors are macromolecules, and to our knowledge, small molecular-based inhibitors have not been reported. In this study, a series of first-in-class small molecular RhoA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. Virtual screening of ～200,000 compounds, followed by SPR-based binding affinity assays resulted in three compounds with binding affinities to RhoA at the micromolar level (compounds 1-3). Compound 1 was selected for further structure modifications in considering binding activity and synthesis ease. Fourty-one new compounds (1, 12a-v, 13a-h, and 14a-j) were designed and synthesized accordingly. It was found that eight (12a, 12j, 14a, 14b, 14d, 14e, 14 g, and 14h) showed high RhoA inhibition activities with IC50 values of 1.24 to 3.00 μM. A pharmacological assay indicated that two compounds (14g and 14 h) demonstrated noticeable vasorelaxation effects against PE-induced contraction in thoracic aorta artery rings and served as good leads for developing more potent cardiovascular agents.

Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium

Aromatic nitro compounds are readily reduced by SnCl2, 2 H2O in alcohol or ethyl acetate or by anhydrous SnCl2 in alcohol where other reducible or acid sensitive groups such as aldehyde, ketone, ester, cyano, halogen and O-benzyl remain unaffected.